Nexalin Technology Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 6

Employees

  • Stock Symbol
  • NXL

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $4.35
  • (As of Monday Closing)

Nexalin Technology General Information

Description

Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Contact Information

Website
www.nexalin.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1776 Yorktown
  • Suite 550
  • Houston, TX 77056
  • United States
+1 (713)
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Services
Other Healthcare Technology Systems
Stock Exchange
NAS
Vertical(s)
TMT, HealthTech, Life Sciences
Corporate Office
  • 1776 Yorktown
  • Suite 550
  • Houston, TX 77056
  • United States
+1 (713)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nexalin Technology Stock Performance

As of 09-Dec-2024, Nexalin Technology’s stock price is $4.35. Its current market cap is $55.9M with 10.6M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.35 $4.36 $0.25 - $4.49 $55.9M 10.6M 1.64M -$0.65

Nexalin Technology Financials Summary

As of 30-Sep-2024, Nexalin Technology has a trailing 12-month revenue of $162K.

In Thousands,
USD 		TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 6,233 (409) (1,644)
Revenue 162 111 1,321 144
EBITDA (5,524) (4,606) (1,638) (5,995)
Net Income (5,555) (4,649) (1,698) (6,078)
Total Assets 5,257 3,632 7,432 754
Total Debt 0 4 755 850
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Nexalin Technology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Nexalin Technology‘s full profile, request access.

Request a free trial

Nexalin Technology Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Nexalin Technology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220023615-A1 Alternating current dynamic frequency stimulation system and method for anxiety, depression, and insomnia (adi) Active 22-Jul-2020
US-20220023616-A1 Alternating current dynamic frequency stimulation system and method for opioid use disorder (oud) and substance use disorder (sud) Pending 22-Jul-2020
US-20220023629-A1 Transcranial alternating current dynamic frequency stimulation (tacs) system and method for alzheimers and dementia Active 22-Jul-2020
CA-3189795-A1 Transcranial alternating current dynamic frequency stimulation (tacs) system and method for alzheimers and dementia Pending 22-Jul-2020
AU-2021311385-A1 Transcranial alternating current dynamic frequency stimulation (tacs) system and method for alzheimers and dementia Pending 22-Jul-2020 A61N1/36025
To view Nexalin Technology’s complete patent history, request access »

Nexalin Technology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nexalin Technology Investments (1)

Nexalin Technology’s most recent deal was a Joint Venture with Joint Venture (Nexalin Technology / Wider Come). The deal was made on 01-Jun-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Joint Venture (Nexalin Technology / Wider Come) 01-Jun-2023 Joint Venture Other Commercial Products
To view Nexalin Technology’s complete investments history, request access »

Nexalin Technology FAQs

  • When was Nexalin Technology founded?

    Nexalin Technology was founded in 2010.

  • Where is Nexalin Technology headquartered?

    Nexalin Technology is headquartered in Houston, TX.

  • What is the size of Nexalin Technology?

    Nexalin Technology has 6 total employees.

  • What industry is Nexalin Technology in?

    Nexalin Technology’s primary industry is Therapeutic Devices.

  • Is Nexalin Technology a private or public company?

    Nexalin Technology is a Public company.

  • What is Nexalin Technology’s stock symbol?

    The ticker symbol for Nexalin Technology is NXL.

  • What is the current stock price of Nexalin Technology?

    As of 09-Dec-2024 the stock price of Nexalin Technology is $4.35.

  • What is the current market cap of Nexalin Technology?

    The current market capitalization of Nexalin Technology is $55.9M.

  • What is Nexalin Technology’s current revenue?

    The trailing twelve month revenue for Nexalin Technology is $162K.

  • What is Nexalin Technology’s annual earnings per share (EPS)?

    Nexalin Technology’s EPS for 12 months was -$0.65.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »